Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event

Core Insights - Microbot Medical Inc. is not experiencing any business disruption due to current geopolitical events, prioritizing employee safety and operational continuity [1][4] - The company has shifted its commercial focus to the U.S. market following FDA clearance of the LIBERTY Endovascular Robotic System, ensuring reliable distribution and service [2] - A full market release of the LIBERTY System is planned for the Society of Interventional Radiology (SIR) conference in April 2026, with efforts to enhance commercial infrastructure [3][5] Company Operations - The company maintains sufficient inventory in the U.S. to support current customers and is actively building additional stock through a third-party logistics partner [2] - Additional sales representatives have been hired to expand coverage into new U.S. territories, along with a Director of Health Economics and Outcomes Research to support commercial expansion [3] Product Information - The LIBERTY System is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to reduce radiation exposure and physical strain [5][6] - The limited market release of the LIBERTY system commenced in late 2025, with the goal of deepening market adoption during the full release [5]